Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre Prospective Controlled Observer Blinded Cohort Study in Patients With Acromegaly to Evaluate the Risk of Cardiac Valvular Regurgitation in Patients Treated With Lanreotide Relative to Patients Treated With Octreotide

NCT00234520 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT00234520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00234520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre Prospective Controlled Observer Blinded Cohort Study in Patients With Acromegaly to Evaluate the Risk of Cardiac Valvular Regurgitation in Patients Treated With Lanreotide Relative to Patients Treated With Octreotide
Lead sponsor
Ipsen
Phase
Observational
Overall status
Completed
Start date
May 31, 2003
Completion date
February 18, 2005
Enrollment
225 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly